Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Xenetic Biosciences's EBITDA for the
three
months ended in Mar. 2026 was €-0.43 Mil. Xenetic Biosciences's Revenue for the
three
months ended in Mar. 2026 was €0.70 Mil. Therefore, Xenetic Biosciences's EBITDA margin for the quarter that ended in Mar. 2026 was -62.18%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Xenetic Biosciences EBITDA Margin % Related Terms
Xenetic Biosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Xenetic Biosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:3XB0 vs ACXP, SILO, GOVX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Xenetic Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenetic Biosciences EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Xenetic Biosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenetic Biosciences (STU:3XB0) has a EBITDA Margin % of -62.18% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xenetic Biosciences and its competitors. According to the industry distribution chart, Xenetic Biosciences ranks #480 out of 940 companies in the Biotechnology industry, placing it in the top 51.1%.
Is Xenetic Biosciences' EBITDA Margin % too high?
Xenetic Biosciences' current EBITDA Margin % is -62.18%. Based on the distribution chart, Xenetic Biosciences ranks #480 out of 940 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Xenetic Biosciences has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Xenetic Biosciences' EBITDA Margin % compare to ACXP and SILO?
According to the Biotechnology industry distribution chart, Xenetic Biosciences ranks #480 out of 940 companies for EBITDA Margin %. This places Xenetic Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Xenetic Biosciences and its competitors. Xenetic Biosciences's current EBITDA Margin % is -62.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenetic Biosciences stock overvalued right now?
Xenetic Biosciences (STU:3XB0) has a current EBITDA Margin % of -62.18%. The stock's GF Value™ is €4.66, compared to a current price of €3.10 — trading 33.5% below its estimated fair value. The current EBITDA Margin % is -62.18%. Xenetic Biosciences' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Xenetic Biosciences (STU:3XB0), the current EBITDA Margin % is -62.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xenetic Biosciences (STU:3XB0) Overvalued in 2026?
Based on GuruFocus' analysis, Xenetic Biosciences stock appears to be undervalued.
The current stock price of €3.10 is trading 33.5% below its estimated GF Value™ of €4.66.
Key valuation signals for STU:3XB0:
EBITDA Margin %: -62.18%
GF Value™: €4.66 vs. price of €3.10 (33.5% below fair value)
No single metric tells the full story. See the STU:3XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
78GF Score
Get the complete analysis for STU:3XB0
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3XB0 has been successfully added to your 
